Citigroup Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $150.00

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price increased by Citigroup from $140.00 to $150.00 in a research report released on Friday, Benzinga reports. The firm currently has a neutral rating on the stock. Other analysts also recently issued research reports about the company. Oppenheimer raised their price objective on Neurocrine Biosciences from […]

Related Keywords

Los Angeles ,California ,United States ,Neurocrine Biosciences ,Davidw Boyer ,Ingrid Delaet ,Needham Company ,Cantor Fitzgerald ,Vanguard Group Inc ,Neurocrine Biosciences Inc ,Capital Partners ,Jpmorgan Chase Co ,Nasdaq ,Citigroup ,Los Angeles Capital Management ,Neurocrine Biosciences Company Profile ,Brown Advisory Inc ,Securities Exchange Commission ,Free Report ,Moderate Buy ,Get Free Report ,Exchange Commission ,Angeles Capital Management ,Neurocrine Biosciences Daily ,Nasdaq Nbix ,Nbix ,Medical ,64125c10 ,Boost Price Target ,Citigroup Inc ,